Eligible patients pay
as little as $0^
for a 90-day supply of
RESTASIS® single-use vials or
3 bottles of RESTASIS MultiDose®
^Patient out-of-pocket costs may vary. Terms and Conditions apply. This offer is only valid for commercially insured patients. Offer not valid for patients enrolled in Medicare, Medicaid, or other federal or state healthcare programs. Please see full Program Terms, Conditions, and Eligibility Criteria here.
RESTASIS® and RESTASIS MultiDose® ophthalmic emulsion are indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca. Increased tear production was not seen in patients currently taking topical anti-inflammatory drugs or using punctal plugs.
RESTASIS® and RESTASIS MultiDose® are contraindicated in patients with known or suspected hypersensitivity to any of the ingredients in the formulation.
POTENTIAL FOR EYE INJURY AND CONTAMINATION: Be careful not to touch the container tip to your eye or other surfaces to avoid potential for eye injury and contamination.
USE WITH CONTACT LENSES: RESTASIS® and RESTASIS MultiDose® should not be administered while wearing contact lenses. If contact lenses are worn, they should be removed prior to the administration of the emulsion. Lenses may be reinserted 15 minutes following administration of RESTASIS® and RESTASIS MultiDose® ophthalmic emulsion.
In clinical trials, the most common adverse reaction following the use of cyclosporine ophthalmic emulsion 0.05% was ocular burning (upon instillation)—17%. Other reactions reported in 1% to 5% of patients included conjunctival hyperemia, discharge, epiphora, eye pain, foreign body sensation, pruritus, stinging, and visual disturbance (most often blurring).
Please see Full Prescribing Information
*Source: Symphony Health Managed Markets Vantage, November 2018 - October 2019. Data are subject to change. Data are not a guarantee of coverage, or partial or full payment, by any payers. Actual benefits determined by respective plan administrators, insurer plans, coverage criteria, and formularies are subject to change without notice. Check each patient’s coverage with applicable insurer. Allergan does not endorse any individual plans. Formulary coverage does not imply efficacy or safety.
†Insurer plans, coverage criteria, and formularies are subject to change without notice. Check each patient’s coverage with the applicable insurer. Allergan does not endorse any individual plans. Formulary coverage comparisons are not intended to imply a comparison of efficacy, safety, therapeutic equivalence, or overall cost of care.
1. Data on file. Allergan, Inc., 1999; Clinical Study Report 192371-002. 2. Data on file. Allergan, Inc., 1999; Clinical Study Report 192371-003.
